P-039

P-039 is a preclinical-stage small molecule non-steroidal anti-inflammatory drug (NSAID) candidate developed by Pangea Pharmaceuticals. It is the lead program in the company's pipeline of "Pangea-NSAIDs" (P-NSAIDs), which are engineered to provide the therapeutic benefits of traditional NSAIDs—such as pain relief and anti-inflammatory activity—while significantly reducing the risk of gastrointestinal (GI) and cardiovascular side effects. P-039 functions by inhibiting cyclooxygenase enzymes (COX-1 and COX-2) and is being developed for the treatment of various pain and inflammatory conditions. The drug utilizes a proprietary modification intended to improve the safety profile for long-term use compared to conventional NSAIDs.